To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
59
ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
GSK Investigational Site
Buffalo, New York, United States
Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab)
Based on standardized response criteria for NHL, responders included participants with CR (complete disappearance of all detectable clinical and radiographic evidence of disease), CRu (more than a 75% decrease in LN size compared to baseline), and PR (\>=50% decrease in LN size and evidence of new lesions). Non-responders included participants with stable disease (SD; \<50% decrease in LN size from baseline) and progressive disease (PD; \>=50% increase in LN size and evidence of new lesions).
Time frame: Maximum of 23 months after the start of treatment
Number of Participants With Complete Remission (CR) at Visit 26
Participants were evaluated for response by an Independent Endpoint Review Committee in accordance with the standardized response criteria for NHL. Participants with CR were defined as those with the complete disappearance of all detectable clinical and radiographic evidence of disease.
Time frame: Maximum of 23 months after the start of treatment
Median Percent Change From Visit 1 (Screening, Week -2) in Tumor Size at Visit 33 (24 Months After the Last Infusion of Ofatumumab)
The tumor size for a participant was computed as the sum of product of diameters (SPD) for the indicator lesions. Reduction in tumor size was calculated as percent change from Visit 1 until Visit 33, separately by radiologist 1 and radiologist 2. Percent change from Visit 1 (Screening, Week -2) = (value at Visit 33 minus value at Visit 1 divided by value at Visit 1) \* 100.
Time frame: Maximum of 24 months after the last infusion of Ofatumumab (Visit 33; median of 33.8 months)
Time to New Anti-follicular Lymphoma (FL) Therapy
Time to new FL therapy is defined as the time from randomization until the time of first administration of the new FL therapy other than ofatumumab. Time to new FL therapy will be censored if participants are lost to follow-up. The censoring date in such cases will be the date of the last attended visit at which the endpoint was assessed.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
Time frame: Followed up to 5 years
Progression-Free Survival (PFS)
PFS is defined as the time from randomization until progression or death.
Time frame: Followed up to 5 years
Duration of Response
The duration of response is defined as the time from the initial response (the first visit at which response was observed) to progression or death.
Time frame: Followed up to 5 years
Percent Change From Visit 1 (Screening) in Peripheral CD19+ and CD20+ Cell Counts at Visit 33 (24 Months After the Last Infusion of Ofatumumab)
The peripheral blood for each participant was collected and analyzed for CD19+ and CD20+ cell counts. CD19+ and CD20+ are B-cell types which are used as an index of a participant's response to treatment.
Time frame: Maximum of 24 months after the last infusion of Ofatumumab (Visit 33; median of 33.8 months)
Number of Participants Who Experienced Any Adverse Event (AEs) From First Treatment to Visit 33 (24 Months After Last Infusion)
An adverse event is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with the treatment. A list of AEs experienced in the study with a frequency threshold of 5% can be found in the AE section.
Time frame: Up to 22 months after study start
Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Visits 1, 28, and 33
HAHA are indicators of immunogenicity to ofatumumab. Blood samples were drawn from participants at Visits 1, 28, and 33 for analysis of HAHA.
Time frame: Visits 1 (Screening), 28 (9 months after last dose), and 33 (24 months after last dose)
Median Percent Change From Visit 1 (Screening) in Serum Complement (CH50) Levels at Visit 22
The peripheral blood for each participant was collected and analyzed for serum complement CH50 levels. Cluster of Differentiation index 50 (CD50) is a human gene which is used as an index of immune response. CD50Percent change from Visit 1 (Screening, Week -2) = (value at Visit 22 minus value at Visit 1 divided by value at Visit 1) \* 100.
Time frame: Visit 1 (Screening, Week -2) and Visit 22 (Week 15)
Number of Participants Who Had a Conversion of BCL-2 t(14;18)-Positive to Negative by Polymerase Chain Reaction (PCR) in Peripheral Blood and Bone Marrow Aspirate and Its Durability Post-therapy
This is a genetic prognostic marker of FL response. The former sponsor decided to not analyze these samples; therefore, no results are presented.
Time frame: Maximum of 6 years follow-up
Cmax and Ctrough at the Sixth Infusion (Week 15, Visit 22)
Cmax is defined as the maximum concentration of drug in plasma samples. Ctrough is defined as the trough plasma concentration (measured concentration at the end of a dosing interval \[taken directly before next administration\]).
Time frame: Week 15 (Visit 22)
AUC(0-inf) and AUC(0-504) After the Sixth Infusion (Week 15, Visit 22)
AUC is defined as the area under the ofatumumab concentration-time curve as a measure of drug exposure. AUC(0-504) is AUC from the start of infusion to 504 hours after the start of the infusion; AUC(0-inf) is AUC from the start of infusion extrapolated to infinity.
Time frame: Week 15 (Visit 22)
Half Life (t1/2) of Ofatumumab at the Sixth Infusion (Week 15, Visit 22)
Half life is defined as the period of time required for the amount of drug in the body to be reduced by half.
Time frame: Week 15 (Visit 22)
CL After the Sixth Infusion (Week 15, Visit 22)
CL is the clearance of drug from plasma, which is defined as the volume of plasma from which the drug is cleared per unit time.
Time frame: Week 15 (Visit 22)
Vss at the Sixth Infusion (Week 15, Visit 22)
Vss is defined as the volume of distribution at steady state of ofatumumab.
Time frame: Week 15 (Visit 22)